LATEST

• REGULATORY Avastin Price to Be Axed by 45% as G1 Rule Hits Originator Biologics
  March 6, 2026

• REGULATORY Forxiga Slapped with 36% Price Cut on PMP Return in FY2026 Revision
  March 6, 2026

• BUSINESS Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
  March 6, 2026

• REGULATORY Japan Panel Clears Joenja, Dojolvi, Bayer MRI Contrast Agent
  March 6, 2026

• BUSINESS Japan Grants First-Ever Approval to iPSC-Based Therapies
  March 6, 2026

• REGULATORY Japan's Revised Drug Distribution Guidelines Take Effect
  March 6, 2026

• BUSINESS Meiji Starts Japan PIII Trial of Rezurock for CLAD
  March 6, 2026

• BUSINESS Meiji Rolls Out Rezurock in Taiwan
  March 6, 2026

• BUSINESS Toray Out-Licenses Parkinson’s Drug to Immunis
  March 6, 2026

• BUSINESS Sawai Pharmaceutical to Promote Toshiomi Nakate to President
  March 6, 2026

• BUSINESS Asahi Kasei Pharma to Rebrand as Asahi Kasei Therapeutics in April
  March 6, 2026

• BUSINESS Keytruda Maintains Top Spot for 29 Straight Months in February: Encise
  March 6, 2026

• REGULATORY Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
  March 5, 2026

• REGULATORY Romiplate to See Steepest Cut in April Market Expansion Re-Pricing
  March 5, 2026

• BUSINESS Takeda Files Japan NDA for Narcolepsy Drug Oveporexton
  March 5, 2026

• BUSINESS Kyowa Kirin Sticks to Long-Term Targets despite Rocatinlimab Setback
  March 5, 2026

• REGULATORY MHLW Clarifies Use of Real-World Data in Drug Applications
  March 5, 2026

• REGULATORY MHLW Expands Eligibility for “Specific-Use Drug” Designation
  March 5, 2026

• REGULATORY MHLW to Launch Priority Review Pathway for Overseas Alternatives amid Drug Shortages
  March 5, 2026

• REGULATORY LDP Health Panel Approves Health Insurance Bill with OTC-Like Drug Charges
  March 5, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »